David A. Siegel Phathom Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $316,641 - $425,365	-35,300 Reduced 68.41%	16,300 $167,000
Q1 2024 May 15, 2024	BUY	$6.21 - $11.05 $179,469 - $319,345	28,900 Added 127.31%	51,600 $547,000
Q4 2023 Feb 14, 2024	BUY	$6.99 - $10.71 $158,673 - $243,117	22,700 New	22,700 $207,000
Q4 2022 Feb 14, 2023	SELL	$9.18 - $11.53 $85,374 - $107,229	-9,300 Reduced 38.59%	14,800 $166,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $56,848 - $106,568	-8,800 Reduced 26.75%	24,100 $267,000
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $31,620 - $79,050	-5,100 Reduced 13.42%	32,900 $278,000
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $68,145 - $118,353	5,900 Added 18.38%	38,000 $517,000
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $279,931 - $520,455	15,700 Added 95.73%	32,100 $631,000
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $279,279 - $335,153	-9,100 Reduced 35.69%	16,400 $526,000
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $192,693 - $235,232	-5,900 Reduced 18.79%	25,500 $863,000
Q1 2021 May 17, 2021	BUY	$33.86 - $48.68 $1.06 Million - $1.53 Million	31,400 New	31,400 $1.18 Million

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.